logo

For the Inventor, By the Inventor

Cranbury, NJ, United States of America

Jonathan Laird Gross

USPTO Granted Patents = 17 

Average Co-Inventor Count = 2.8

ph-index = 2

Forward Citations = 15(Granted Patents)


Location History:

  • Robbinsville, NJ (US) (2003 - 2004)
  • Cranbury, NJ (US) (2006 - 2011)

Company Filing History:

goldMedal17 out of 1,309 
 
Wyeth
 patents

Years Active: 2003-2011

Loading Chart...
17 patents (USPTO):Explore Patents
1. 7935719 - N-substituted-azacyclylamines as histamine-3 antagonists (2011-05-03),
2. 7820825 - N-substituted-azacyclylamines as histamine-3 antagonists (2010-10-26),
3. 7803825 - Aminoalkylazole derivatives as histamine-3 antagonists (2010-09-28),
4. 7728155 - Dihydrobenzofuranyl alkanamines and methods for using same as cns agents (2010-06-01),
5. 7470799 - Dihydrobenzofuran derivatives and uses thereof (2008-12-30),
6. 7435837 - Dihydrobenzofuranyl alkanamine derivatives and methods for using same (2008-10-14),
7. 7368477 - Benzofuranyl alkanamine derivatives and uses thereof (2008-05-06),
8. 7365095 - Chromane and chromene derivatives and uses thereof (2008-04-29),
9. 7227023 - Quinoline 3-amino chroman derivatives (2007-06-05),
10. 7008944 - Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-Dioxino[2,3-f]quinoxaline (2006-03-07),
11. 6821981 - Azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]-quinoline as 5-HT1A antagonists (2004-11-23),
12. 6750364 - Bridged tricyclic analogs of 2-(carboxycyclopropyl)glycine as inhibitors of glutamate transport (2004-06-15),
13. 6716998 - Process for synthesis of 2-yl chroman derivatives (2004-04-06),
14. 6700001 - Process for stereoselective synthesis of 2-hydroxymethyl chromans (2004-03-02),
15. 6689905 - Stereoisomers of 3-aminotricyclo[2.2.1.0(2.6)]heptane-1,3-dicarboxylic acid (2004-02-10),

Title: The Innovative Contributions of Jonathan Laird Gross

Introduction

Jonathan Laird Gross is a prominent inventor based in Cranbury, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target the central nervous system. With a total of 17 patents to his name, Gross has established himself as a key figure in innovation.

Latest Patents

Among his latest patents are the N-substituted-azacyclylamines as histamine-3 antagonists. This invention provides a compound of formula I and outlines its use for the treatment of central nervous system disorders related to or affected by the histamine-3 receptor. The detailed specifications describe the variables involved in this innovative compound.

Career Highlights

Jonathan Laird Gross is currently associated with Wyeth, a well-known pharmaceutical company. His work at Wyeth has allowed him to focus on groundbreaking research and development in the field of medicinal chemistry. His contributions have been instrumental in advancing therapeutic options for various neurological conditions.

Collaborations

Throughout his career, Gross has collaborated with notable colleagues, including Gary Paul Stack and Hong Gao. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Jonathan Laird Gross exemplifies the spirit of innovation in the pharmaceutical industry. His extensive patent portfolio and collaborative efforts highlight his commitment to advancing medical science. His work continues to impact the treatment of central nervous system disorders, showcasing the importance of inventors in shaping the future of healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…